Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice
Article first published online: 14 DEC 2009
Copyright © 2010 American Society for Bone and Mineral Research
Journal of Bone and Mineral Research
Volume 25, Issue 2, pages 178–189, February 2010
How to Cite
Kramer, I., Loots, G. G., Studer, A., Keller, H. and Kneissel, M. (2010), Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res, 25: 178–189. doi: 10.1359/jbmr.090730
- Issue published online: 19 FEB 2010
- Article first published online: 14 DEC 2009
- Manuscript Accepted: 8 JUL 2009
- Manuscript Revised: 7 MAY 2009
- Manuscript Received: 16 JAN 2009
- 1Osteoporosis in men and women. Clin Cornerstone. 2006; 8: 28–39..
- 2Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26: 688–703., , , et al.
- 3Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118: 421–428., , .
- 4A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991; 254: 1024–1026., , , et al.
- 5Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994; 15: 717–723., , , et al.
- 6Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 2008; 42: 806–818., , , , , .
- 7Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 3632–3638., .
- 8Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439–446., , , , , .
- 9Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278: 50259–50272., , , et al.
- 10Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40: 1434–1446..
- 11SOST is a target gene for PTH in bone. Bone. 2005; 37: 148–158., .
- 12Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577–4583., , , et al.
- 13Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942., , , et al.
- 14Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci. 2007; 1116: 281–290..
- 15PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res. 1995; 10: 1935–1943 ., .
- 16Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res. 2001; 16: 448–456., , , , , .
- 17SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16: 319–327., , , .
- 18Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19: 1842–1844., , , et al.
- 19Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267–6276., , , et al.
- 20Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928–935., , , et al.
- 21Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860–869., , , et al.
- 22Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537–543., , , et al.
- 23Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577–589., , , et al.
- 24Identification of a 52-kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91–97., , , et al.
- 25A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144–152., , , et al.
- 26Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analogue SDZ PTS 893 or human PTH(1–34). Bone. 2001; 28: 237–250., , .
- 27Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595–610., , , et al.
- 28Generation of BAC transgenic mice. Methods Mol Biol. 2004; 256: 159–182., , , .
- 29Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007; 38: 261–269., , , et al.
- 30Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22: 1957–1967 ., , , et al.
- 31Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone. 2003; 32: 513–520., , , et al.
- 32Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16: 1575–1582., , , , .
- 33Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35: 828–835., , , et al.
- 34Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22: 19–28., , , et al.
- 35Genetic variability in adult bone density among inbred strains of mice. Bone. 1996; 18: 397–403., , , .
- 36Parathyroid hormone: a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005; 5: 612–617., .
- 37Progress, paradox, and potential: parathyroid hormone research over five decades. Ann NY Acad Sci. 2007; 1117: 196–208., .,
- 38Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883–19887., , , , et al.
- 39SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770–26775., , .
- 40Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635–2643., .
- 41In vivo analysis of Wnt signaling in bone. Endocrinology. 2007; 148: 2630–2634., .
- 42The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007; 19: 376–382., .
- 43Wnt signaling: a win for bone. Arch Biochem Biophys. 2008; 473: 112–116., , .
- 44The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281: 23698–23711., , , et al.
- 45PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res. 2007; 22: 394–402., , , et al.
- 46Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007; 210: 352–357., , , , .
- 47Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005; 95: 1178–1190., , , et al.
- 48Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147: 2583–2590., , , et al.
- 49PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3β in osteoblastic Saos-2 cells. J Cell Biochem. 2008; 104: 304–317., , , , , .
- 50Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968–2679., , , et al.